Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TNFA elevation

Other names: Tumor Necrosis Factor, Tumor Necrosis Factor Ligand Superfamily Member 2, Cachectin, TNF-Alpha, TNFSF2, TNF-A, TNFA, Tumor Necrosis Factor (TNF Superfamily, Member 2), Tumor Necrosis Factor Ligand 1F, Tumor Necrosis Factor-Alpha, TNF Superfamily, Member 2, TNF Macrophage-Derived, TNF Monocyte-Derived, APC1 Protein, TNLG1F
Entrez ID:
Related biomarkers:
TAK-243 increases tumor immunogenicity enhancing systemic anti-tumor immune response and tumor regression in combination with immune checkpoint inhibition in a syngeneic model of lymphoma (AACR 2023)
Furthermore, re-inoculation of subjects that exhibited complete regression of tumor masses with A20 cells showed no growth of new tumors. Taken together, these data suggest that intratumor injection of TAK-243 has potential to act as an in situ vaccine which increases anti-tumor immunogenicity and primes tumors for response to ICIs.
Combination therapy • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • GZMB (Granzyme B)
TNFA elevation • GZMB elevation
Over expression of mTOR gene predicts overall survival in myelodysplastic syndromes. (PubMed, Mol Biol Rep)
Our study showed an elevation of TNF and AMPK signalling pathways in MDS. TNF signalling might be mediating the proliferative advantage to myeloid clonal cells (mutation carrying cells) over normal cells, whereas, AMPK signalling could be acting as protector against it (favouring normal cells). Hence it would be interesting to explore the functions and pathways associated with mTOR, AMPK, MAPK8 and JUNB in myelopoiesis related diseases like MDS.
mTOR (Mechanistic target of rapamycin kinase) • ASXL1 (ASXL Transcriptional Regulator 1) • CD34 (CD34 molecule) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit) • MAPK8 (Mitogen-activated protein kinase 8)
ASXL1 mutation • TNFA elevation • MTOR overexpression
Clinical and Basic Evaluation of the Effects of Upregulated TNFAIP3 Expression on Colorectal Cancer. (PubMed, Dis Markers)
Our evidences suggest the promising potential of utilizing TNFAIP3 and NFκB as important reference indices for determining the prognostic outcome of CRC. Furthermore, we revealed that TNFAIP3 overexpression inhibited CRC cell proliferation, invasion, and migration.
TNFAIP3 (TNF Alpha Induced Protein 3)
TNFA elevation • TNFAIP3 overexpression
Weakly Acidic Bile Is a Risk Factor for Hypopharyngeal Carcinogenesis Evidenced by DNA Damage, Antiapoptotic Function, and Premalignant Dysplastic Lesions In Vivo. (PubMed, Cancers (Basel))
Weakly acidic pH increases the risk of bile-related hypopharyngeal neoplasia. The oncogenic properties of biliary esophageal reflux on the epithelium of the upper aerodigestive tract may not be fully modified when antacid therapy is applied. We believe that due to bile content, alternative therapeutic strategies using specific inhibitors of relevant molecular pathways or receptors may be considered in patients with refractory GERD.
Journal • IO biomarker
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21)
BCL2 overexpression • BCL2 expression • TNFA elevation • miR-21 overexpression
[VIRTUAL] Combining irreversible electroporation with TLR7 and CD40 agonists confers systemic anti-tumor immunity in a murine pancreatic cancer model (AACR-II 2020)
These data suggest that local delivery of CD40Ab and TLR7 agonists augment the systemic immune effects of IRE and have the potential to improve the overall survival of patients undergoing IRE for locally advanced PC by reducing distant recurrence.
Preclinical • Tumor Mutational Burden • IO biomarker
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CD44 • IL2 (Interleukin 2) • CD40 (CD40 Molecule)
TMB-L • TNFA elevation